1001 ET - The steep selloff in Sarepta Therapeutics shares following the death of a patient who received its Elevidys gene therapy is likely overdone, Mizuho's Uy Ear says in a brief note. Mizuho says while acute liver injury is a known side effect of Elevidys, this is the first case of acute liver failure leading to death after more than 800 patients have been treated, and that the individual who died had a recent cytomegalovirus infection, which can damage the liver. Mizuho, with an outperform rating and $190 price target on Sarepta, says it still see the Elevidys benefit/risk profile as positive. Sarepta tumbles 23% to $78. (colin.kellaher@wsj.com)
(END) Dow Jones Newswires
March 18, 2025 10:01 ET (14:01 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
